Adeno‐Associated Virus‐Induced Humanized Hypertensive Mouse Model Validates N‐Acetylgalactosamine‐Conjugated Small Interfering RNA Targeting Angiotensinogen as a Long‐Acting Antihypertensive Therapy
Year: 2026
Type: article
Abstract: BACKGROUND: Hypertension remains a leading cause of global morbidity and mortality, yet current therapeutic strategies lack sustained efficacy and long-term stability. Our study aimed to construct a humanized rodent model for drugs development especially currently prevalent small interfering RNA medication. METHODS: A humanized hypertensive mouse model was generated by subcutaneous injection of neonatal mice with adeno-associated viruses encoding hAGT (human angiotensinogen) and hRENIN (human renin). Blood pressure was monitored weekly via tail-cuff plethysmography. Expression of hAGT and hRENIN was assessed by ELISA, Western blot, and reverse transcription quantitative polymerase chain reaction. Cardiac function was evaluated by echocardiography at 4 and 6 months postinjection. Hypertension-associated comorbidities were examined through histological analysis and ELISA. A modified N-acetylgalactosamine-conjugated small interfering RNA targeting human hepatic AGT (GalNAc-siAGT) was screened and subcutaneously administered to humanized hypertensive mice, either alone or in combination with valsartan, to evaluate therapeutic efficacy. RESULTS: The dual adeno-associated virus-induced humanized hypertensive model exhibited a sustained hypertension for 6 months and manifested prevalent comorbidities, including heart failure and kidney disease. This modified GalNAc-siAGT demonstrated significant activity in knocking down hAGT both in vitro and in vivo. Only a single subcutaneous injection of GalNAc-siAGT in humanized hypertensive mice led to a sustained reduction in blood pressure lasting for 2 months, accompanied by cardio- and renoprotective effects. Moreover, combining GalNAc-siAGT with the renin-angiotensin system blocker, valsartan, significantly enhanced therapeutic efficacy. CONCLUSIONS: Our study validated the antihypertensive therapeutic effect of GalNAc-siAGT in a humanized hypertensive murine model while highlighting the translational potential of this model for clinical drug development.
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,810
OpenAlex ID: W7225900233
